GGrantIndex
← Search

PHASE I DOSE ESCALATION TRIAL OF ZENECA ZD9331

$16,409M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Abstract

The primary objective of this trial is to reach the dose at which dose-limiting toxicity of Zeneca ZD 9331 occurs and define the maximum tolerated dose when the drug is administered as a 30 minute infusion once every three weeks. This is an open-label, noncomparative, dose-escalation trial of this folate analogue and TS inhibitor.

View original record on NIH RePORTER →